Literature DB >> 26043161

Novel routes to either racemic or enantiopure α-amino-(4-hydroxy-pyrrolidin-3-yl)acetic acid derivatives and biological evaluation of a new promising pharmacological scaffold.

Samy Cecioni1, Kaïss Aouadi1, Julie Guiard1, Sandrine Parrot2, Nathalie Strazielle3, Sandrine Blondel3, Jean-François Ghersi-Egea3, Christian Chapelle4, Luc Denoroy5, Jean-Pierre Praly1.   

Abstract

Cycloaddition between (+) or (-)-menthone-derived nitrones and N-benzyl-3-pyrroline afforded enantiopure spiro-fused heterocycles. The reaction occurred enantio- and diastereo-selectively on the less hindered side of the nitrone, the 3-pyrroline N-benzyl group being oriented outwards, thus controlling the configurations of three simultaneously created chiral centers. From either (+) or (-)-menthone, both enantiomeric cycloadducts were synthesized in excellent yield. Removing the chiral auxiliary and the N-benzyl group delivered a series of enantiopure 4-hydroxy-3-glycinyl-pyrrolidine derivatives in 3-5 steps and 36 to 81 overall yields. Using two other achiral nitrones, shorter routes to racemic analogues were developed. Two of the synthesized compounds markedly lowered extracellular glutamate level and modestly interacted with cannabinoid type-1 receptors. As these two neuroactive compounds were devoid of in vitro toxicity and did not cross the blood brain interface, they might represent potential pharmacological agents to target peripheral organs.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Blood brain barrier; CNS receptors; Chiral nitrone; Cycloaddition; Isoxazolidine; Neuroactive analogs; Pyrrolidine

Mesh:

Substances:

Year:  2015        PMID: 26043161     DOI: 10.1016/j.ejmech.2015.05.017

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Inhibitory Activity of Pyrroloisoxazolidine Derivatives against Chlamydia trachomatis.

Authors:  Min Ni; Shunxin Xu; Ziyi Liu; Yin Xue; Wenxia Xie; Shengju Yang; Lingyan Liu; Xiaofeng Bao
Journal:  Biomed Res Int       Date:  2021-03-13       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.